An investigation highlighted concerns about for-profit dialysis clinics in the U.S., which are linked to worse patient outcomes and reduced transplant access. DaVita and Fresenius, controlling over 60% of dialysis centers, are part of the for-profit companies making up nearly 80% of the market. Research indicates that after large companies acquired smaller clinics, there were negative changes such as less trained staff replacing experienced nurses, increased patient loads per employee and shifts in medication administration. These changes may contribute to higher mortality rates among U.S. dialysis patients compared to other developed countries.
Please see full publication below for more information.
